EGFR intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancerVASHIST, Yogesh K; TRUMP, Florian; PANTEL, Klaus et al.Targeted oncology. 2014, Vol 9, Num 1, pp 43-52, issn 1776-2596, 10 p.Article

Curcumin and lung cancer—a reviewMEHTA, Hiren J; PATEL, Vipul; SADIKOT, Ruxana T et al.Targeted oncology. 2014, Vol 9, Num 4, pp 295-310, issn 1776-2596, 16 p.Article

Insufficiency of peripheral blood as a substitute tissue for detecting EGFR mutations in lung cancer: a meta-analysisZHIJUN LI; YONGJUN ZHANG; WENLONG BAO et al.Targeted oncology. 2014, Vol 9, Num 4, pp 381-388, issn 1776-2596, 8 p.Article

Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer—Study BES 06VILLANUEVA, C; ROMIEU, G; SALVAT, J et al.Targeted oncology. 2013, Vol 8, Num 2, pp 137-143, issn 1776-2596, 7 p.Article

The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patientsAL-MARRAWI, Mhd Y; RINI, Brian I; KOLLMANNSBERGER, Christian et al.Targeted oncology. 2013, Vol 8, Num 3, pp 203-209, issn 1776-2596, 7 p.Article

Gastric cancer (GC) patients with hedgehog pathway activation: PTCH1 and GLI2 as independent prognostic factorsSU JIN LEE; DO, In-Gu; JEEYUN LEE et al.Targeted oncology. 2013, Vol 8, Num 4, pp 271-280, issn 1776-2596, 10 p.Article

Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancerSHIMIZU, Katsuhiko; YUKAWA, Takuro; HIRAMI, Yuji et al.Targeted oncology. 2013, Vol 8, Num 4, pp 237-242, issn 1776-2596, 6 p.Article

Suppression of the proliferation of human U-87 MG glioblastoma cells by new antagonists of growth hormone-releasing hormone in vivo and in vitroJASZBERENYI, Miklos; SCHALLY, Andrew V; BLOCK, Norman L et al.Targeted oncology. 2013, Vol 8, Num 4, pp 281-290, issn 1776-2596, 10 p.Article

A review on various targeted anticancer therapiesJUNJIE LI; FENG CHEN; MIRANDA CONA, Marlein et al.Targeted oncology. 2012, Vol 7, Num 1, pp 69-85, issn 1776-2596, 17 p.Article

Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastomaLA MADRID, Andres Morales; CAMPBELL, Nicholas; SMITH, Sonali et al.Targeted oncology. 2012, Vol 7, Num 3, pp 199-210, issn 1776-2596, 12 p.Article

Chronic therapy in gastrointestinal stromal tumours (GISTs): the big gap between theory and practiceSAPONARA, Maristella; ABBONDANZA PANTALEO, Maria; NANNINI, Margherita et al.Targeted oncology. 2012, Vol 7, Num 4, pp 243-246, issn 1776-2596, 4 p.Article

Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinomaNEUHAUS, Thomas; LUYKEN, Joachim.Targeted oncology. 2012, Vol 7, Num 4, pp 247-251, issn 1776-2596, 5 p.Article

Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancerPLATANIA, Marco; AGUSTONI, Francesco; FORMISANO, Barbara et al.Targeted oncology. 2011, Vol 6, Num 3, pp 181-186, issn 1776-2596, 6 p.Article

Targets for therapy in ependymomaSHONKA, Nicole A.Targeted oncology. 2011, Vol 6, Num 3, pp 163-169, issn 1776-2596, 7 p.Article

The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomasVEMULAPALLI, Sushma; MITA, Alain; ALVARADO, Yesid et al.Targeted oncology. 2011, Vol 6, Num 1, pp 29-39, issn 1776-2596, 11 p.Article

Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy : Special focus: Response prediction: Coordinated by E. Van Cutsem and F. CiardielloPADHANI, Anwar R; ALAM KHAN, Aftab.Targeted oncology. 2010, Vol 5, Num 1, pp 39-52, issn 1776-2596, 14 p.Article

Targeting integrins in malignant gliomaTABATABAI, Ghazaleh; WELLER, Michael; NABORS, Burt et al.Targeted oncology. 2010, Vol 5, Num 3, pp 175-181, issn 1776-2596, 7 p.Article

Molecular markers in gliomas: impact for the clinicianHOFER, Silvia; LASSMAN, Andrew B.Targeted oncology. 2010, Vol 5, Num 3, pp 201-210, issn 1776-2596, 10 p.Article

Immune therapeutic targeting of glioma cancer stem cellsMUSTAPHA AZIZ HATIBOGLU; JUN WEI; ADAM SAUH GEE WU et al.Targeted oncology. 2010, Vol 5, Num 3, pp 217-227, issn 1776-2596, 11 p.Article

Molecular imaging in clinical trialsJOSEPHS, Debra; SPICER, James; O'DOHERTY, Michael et al.Targeted oncology. 2009, Vol 4, Num 3, pp 151-168, issn 1776-2596, 18 p.Article

Optical tomography of breast cancer—monitoring response to primary medical therapyENFIELD, Louise C; GIBSON, Adam P; HEBDEN, Jeremy C et al.Targeted oncology. 2009, Vol 4, Num 3, pp 219-233, issn 1776-2596, 15 p.Article

Successful treatment of brain metastases from renal cell cancer using radiotherapy in combination with sorafenibSTIERNER, Ulrika; TAHERI-KADKHODA, Zahra.Targeted oncology. 2008, Vol 3, Num 4, pp 259-264, issn 1776-2596, 6 p.Article

Advanced non-small cell lung cancer therapy : historical and future perspectivesRECK, M; GATZEMEIER, U.Targeted oncology. 2008, Vol 3, Num 3, pp 135-147, issn 1776-2596, 13 p.Article

The role of positron emission tomography in staging of non-small cell lung cancerRANKIN, Sheila C.Targeted oncology. 2008, Vol 3, Num 3, pp 149-159, issn 1776-2596, 11 p.Article

Molecular targeted therapy for advanced hepatocellular carcinomaYING CHUN SHEN; HSU, Chiun; CHENG, Ann Lii et al.Targeted oncology. 2007, Vol 2, Num 4, pp 199-210, issn 1776-2596, 12 p.Article